PURPOSE: To prospectively evaluate the ability of macromolecular contrast medium (MMCM)-enhanced dynamic magnetic resonance (MR) imaging to depict vascular changes in response to cyclooxygenase-2 (COX-2) inhibition of angiogenesis in a human breast cancer model. MATERIALS AND METHODS: The institutional committee for animal research approved this study. A human breast cancer cell line, MDA-MB-231, was implanted in 30 female homozygotous athymic rats that were alternately assigned to either a drug treatment group that received celecoxib on a daily basis for 7 days or a control group that received saline. Each animal underwent MR imaging after intravenous administration of a high-molecular-weight contrast agent at baseline and again 24 hours and 7 days after administration. Eleven rats in each group successfully underwent all three studies and had data sets of sufficient technical quality. A bidirectional two-compartment tissue model was used to estimate transendothelial permeability (K(PS)) and fractional plasma volume (fPV) for each tumor. Microvessel density was also measured to enable histologic assessment of angiogenesis. Repeated-measures analysis of variance and unpaired two-tailed t tests were used to evaluate differences in mean values between MR examinations performed in the same rats and between baseline values in treated and control rats, respectively. RESULTS: MR imaging-assayed microvascular K(PS) decreased significantly after 7 days of treatment with celecoxib (P < .05), but it was not significantly changed after 7 days in the control group. Likewise, microvascular density, a histologic surrogate of angiogenesis, was significantly (P < .05) lower in the treatment group than in the control group. The fPV did not significantly change in either group. CONCLUSION: Dynamic MR imaging revealed microvascular permeability to a high-molecular-weight contrast agent was significantly reduced by treatment with celecoxib.
PURPOSE: To prospectively evaluate the ability of macromolecular contrast medium (MMCM)-enhanced dynamic magnetic resonance (MR) imaging to depict vascular changes in response to cyclooxygenase-2 (COX-2) inhibition of angiogenesis in a humanbreast cancer model. MATERIALS AND METHODS: The institutional committee for animal research approved this study. A humanbreast cancer cell line, MDA-MB-231, was implanted in 30 female homozygotous athymic rats that were alternately assigned to either a drug treatment group that received celecoxib on a daily basis for 7 days or a control group that received saline. Each animal underwent MR imaging after intravenous administration of a high-molecular-weight contrast agent at baseline and again 24 hours and 7 days after administration. Eleven rats in each group successfully underwent all three studies and had data sets of sufficient technical quality. A bidirectional two-compartment tissue model was used to estimate transendothelial permeability (K(PS)) and fractional plasma volume (fPV) for each tumor. Microvessel density was also measured to enable histologic assessment of angiogenesis. Repeated-measures analysis of variance and unpaired two-tailed t tests were used to evaluate differences in mean values between MR examinations performed in the same rats and between baseline values in treated and control rats, respectively. RESULTS: MR imaging-assayed microvascular K(PS) decreased significantly after 7 days of treatment with celecoxib (P < .05), but it was not significantly changed after 7 days in the control group. Likewise, microvascular density, a histologic surrogate of angiogenesis, was significantly (P < .05) lower in the treatment group than in the control group. The fPV did not significantly change in either group. CONCLUSION: Dynamic MR imaging revealed microvascular permeability to a high-molecular-weight contrast agent was significantly reduced by treatment with celecoxib.
Authors: Clemens C Cyran; Yanjun Fu; Victor Rogut; Bundit Chaopathomkul; Michael F Wendland; David M Shames; Robert C Brasch Journal: Acad Radiol Date: 2013-10 Impact factor: 3.173
Authors: Clemens C Cyran; Barbara Sennino; Yanjun Fu; Victor Rogut; David M Shames; Bundit Chaopathomkul; Michael F Wendland; Donald M McDonald; Robert C Brasch; Hans-Juergen Raatschen Journal: Eur J Radiol Date: 2011-09-01 Impact factor: 3.528
Authors: Xia Li; E Brian Welch; A Bapsi Chakravarthy; Lei Xu; Lori R Arlinghaus; Jaime Farley; Ingrid A Mayer; Mark C Kelley; Ingrid M Meszoely; Julie Means-Powell; Vandana G Abramson; Ana M Grau; John C Gore; Thomas E Yankeelov Journal: Magn Reson Med Date: 2011-11-29 Impact factor: 4.668
Authors: Clemens C Cyran; Barbara Sennino; Bundit Chaopathomkul; Yanjun Fu; Victor S Rogut; David M Shames; Michael F Wendland; Donald M McDonald; Robert C Brasch Journal: Eur Radiol Date: 2008-07-30 Impact factor: 5.315
Authors: Clemens C Cyran; Barbara Sennino; Bundit Chaopathomkul; Yanjun Fu; Victor Rogut; David M Shames; Michael F Wendland; Donald M McDonald; Robert C Brasch Journal: Invest Radiol Date: 2008-05 Impact factor: 6.016
Authors: Hans-Juergen Raatschen; Yanjun Fu; Robert C Brasch; Hubertus Pietsch; David M Shames; Benjamin M Yeh Journal: Invest Radiol Date: 2009-05 Impact factor: 6.016
Authors: Barbara Sennino; Hans-Juergen Raatschen; Michael F Wendland; Yanjun Fu; Weon-Kyoo You; David M Shames; Donald M McDonald; Robert C Brasch Journal: Magn Reson Med Date: 2009-09 Impact factor: 4.668